Our group is interested in evaluating early effects of dietary interventions on bone loss. Postmenopausal women lose bone following reduction in estrogen which leads to increased risk of fracture. Traditional means of monitoring bone loss and effectiveness of treatments include changes in bone density, which takes 6 months to years to observe effects, and changes in biochemical markers of bone turnover, which are highly variable and lack specificity. Prelabeling bone with 41 Ca and measuring urinary 41 Ca excretion with accelerator mass spectrometry provides a sensitive, specific, and rapid approach to evaluating effectiveness of treatment. To better understand 41 Ca technology as a tool for measuring effective treatments on reducing bone resorption, we perturbed bone resorption by manipulating dietary calcium in rats. We used 3 H-tetracycline ( 3 H-TC) as a proxy for 41 Ca and found that a single dose is feasible to study bone resorption. Suppression of bone resorption, as measured by urinary 3 H-TC, by dietary calcium was observed in rats stabilized after ovariectomy, but not in recently ovariectomized rats.